AI assistant
NovoCure Ltd — Director's Dealing 2021
Jun 11, 2021
31949_dirs_2021-06-11_ba3faff9-f4ed-4031-97e9-9d9b50043544.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2021-06-09
Reporting Person: HILLEMAN JERYL L (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-09 | Restricted Stock Units | A | 814 | — | Acquired | 4214 | Direct |
| 2021-06-09 | Ordinary Shares | D | 1270 | $210.01 | Disposed | 2944 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-09 | Options to Buy Ordinary Shares | $211.89 | A | 1499 | Acquired | 2031-06-09 | Ordinary Shares (1499.0) | Direct |
Footnotes
F1: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders.
F2: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Ms. Hilleman.
F3: Options to buy 1,499 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders.